Ben R Taylor insider trades: Recursion Pharmaceuticals (RXRX) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ben reports to the SEC
Open-market buys and sales
4 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | RXRX | ↓ Sell | 7,956 | $3.39 | $27K | Direct | Mar 18, 2026 (1d) |
| Feb 18, 2026 | RXRX | ↓ Sell | 13,426 | $3.08 | $41K | Direct | Feb 19, 2026 (1d) |
| Dec 29, 2025 | RXRX | ↓ Sell | 21,383 | $4.18 | $89K | Direct | Dec 30, 2025 (1d) |
| Jun 14, 2019 | TYME | ↑ Buy | 10,000 | $1.01 | $10K | Direct | Jun 17, 2019 (3d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RXRX insiders
Open-market trades in the last 12 months
About Ben R Taylor's insider trades
Ben R Taylor is Chief Financial Officer at Recursion Pharmaceuticals (RXRX). Since Jun 14, 2019, Ben has reported 1 open-market purchase worth $10K and 3 sales worth $158K on SEC Form 4. In the last 12 months: 3 sales ($158K).
Their filings also include shares withheld for taxes (20 filings), grants and awards (7 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RXRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.